BMO Capital Markets slashes price target on Gilead Sciences Inc. [GILD] – find out why.


Gilead Sciences Inc. [NASDAQ: GILD] traded at a high on 04/25/22, posting a 0.64 gain after which it closed the day’ session at $62.65. The company report on April 25, 2022 that Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


— Approval is Supported by Phase 2/3 Data Demonstrating the Safety and Tolerability Profile and Clinical Improvement Outcome in Hospitalized Pediatric Patients Treated with Veklury –.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including hospitalization or death. This approval follows the recent sNDA approval for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19.

The results of the trading session contributed to over 7430372 shares changing hands. Over the past one week, the price volatility of Gilead Sciences Inc. stands at 2.19% while the volatility over the past one month is 1.88%.

The market cap for GILD stock reached $80.38 billion, with 1.26 billion shares outstanding and 1.25 billion shares in the current float. Compared to the average trading volume of 11.12M shares, GILD reached a trading volume of 7430372 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Gilead Sciences Inc. [GILD]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $70.27 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BMO Capital Markets have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 28, 2022. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $72 to $70. The new note on the price target was released on February 02, 2022, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another drop from $77 to $75, while Truist kept a Hold rating on GILD stock. On February 02, 2022, analysts decreased their price target for GILD shares from 87 to 85.

The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.22, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 2.94. The Price to Book ratio for the last quarter was 3.74, with the Price to Cash per share for the same quarter was set at 5.08. Price to Free Cash Flow for GILD in the course of the last twelve months was 11.16 with Quick ratio for the last quarter at 1.10.

How has GILD stock performed recently?

Gilead Sciences Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.74. With this latest performance, GILD shares gained by 5.94% in over the last four-week period, additionally sinking by -6.83% over the last 6 months – not to mention a drop of -4.73% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 57.07, with the RSI for the last a single of trading hit 57.98, and the three-weeks RSI is set at 54.42 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 60.59, while it was recorded at 63.01 for the last single week of trading, and 67.22 for the last 200 days.

Gilead Sciences Inc. [GILD]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +37.27 and a Gross Margin at +75.88. Gilead Sciences Inc.’s Net Margin is presently recorded at +22.74.

Return on Equity for this stock inclined to 31.70, with Return on Assets sitting at 9.13.

Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.

Earnings analysis for Gilead Sciences Inc. [GILD]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to -0.56%.

Insider trade positions for Gilead Sciences Inc. [GILD]

There are presently around $63,140 million, or 83.20% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 118,961,206, which is approximately -1.671% of the company’s market cap and around 0.10% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 107,156,981 shares of the stock with an approximate value of $6.67 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.59 billion in GILD stock with ownership of nearly 0.569% of the company’s market capitalization.

Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 839 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 54,271,994 shares. Additionally, 728 investors decreased positions by around 49,134,226 shares, while 192 investors held positions by with 910,890,494 shares. The mentioned changes placed institutional holdings at 1,014,296,714 shares, according to the latest SEC report filing. GILD stock had 185 new institutional investments in for a total of 5,383,357 shares, while 124 institutional investors sold positions of 5,917,122 shares during the same period.